ArticleJournal of the American College of Surgeons2025
Association of Guideline-Concordant Care with Superior Survival Outcomes for Clinical T2N0M0 Esophageal Squamous Cell Carcinoma.
Article in Journal of the American College of Surgeons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundFor patients with clinical T2N0M0 (cT2N0M0) esophageal squamous cell carcinoma (ESCC), upfront esophagectomy is recommended for low-risk tumors (tumor size less than 3 cm, low-grade histology), and neoadjuvant chemoradiation with esophagectomy or chemoradiation alone is recommended for high-risk tumors (tumor size 3 cm or greater, high-grade histology). The objectives of this study were to (1) describe the treatment strategies used for patients with cT2N0M0 ESCC and (2) analyze survival outcomes for patients according to treatment strategy and tumor risk category. STUDY
designWe performed a retrospective cohort analysis of patients with cT2N0M0 ESCC in the National Cancer Database from 2006 to 2020 comparing patients by tumor risk categories. We compared characteristics of patients according to treatment strategy using bivariate analyses. We performed multivariable Cox regressions comparing overall survival outcomes of patients according to treatment strategy and tumor risk category.
resultsOf the included patients, 145 of 890 (16.3%) with cT2N0M0 ESCC underwent esophagectomy, 176 of 890 (19.8%) underwent neoadjuvant chemoradiation with esophagectomy, and 418 of 890 (47.0%) underwent chemoradiation. Among patients with low-risk cT2N0M0 ESCC, 44 of 222 (19.8%) underwent esophagectomy. Among patients with high-risk cT2N0M0 ESCC, 126 of 668 (18.9%) underwent neoadjuvant chemoradiation with esophagectomy and 332 of 668 (49.7%) underwent chemoradiation therapy. Patients with high-risk tumors undergoing chemoradiation had a 53% higher risk of death than patients with high-risk tumors undergoing neoadjuvant chemoradiation with esophagectomy (adjusted hazard ratio 1.53 [1.15 to 2.05]).
conclusionsApproximately half of patients with cT2N0M0 ESCC received guideline-concordant care. Chemoradiation therapy is overused in patients with high-risk tumors and upfront esophagectomy is underused in patients with low-risk tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.